Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price target of $1.50 for the company and are anticipating that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given Cesca Therapeutics an industry rank of 102 out of 255 based on the ratings given to related companies.

A number of equities research analysts have weighed in on KOOL shares. Zacks Investment Research upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research note on Wednesday, August 22nd. ValuEngine upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 4th.

Shares of Cesca Therapeutics stock traded down $0.02 during midday trading on Wednesday, hitting $0.35. The company had a trading volume of 1,100 shares, compared to its average volume of 760,882. The company has a market cap of $8.17 million, a price-to-earnings ratio of -0.36 and a beta of -0.96. The company has a current ratio of 1.93, a quick ratio of 0.97 and a debt-to-equity ratio of 0.80. Cesca Therapeutics has a 1-year low of $0.22 and a 1-year high of $6.44.

Cesca Therapeutics (NASDAQ:KOOL) last announced its quarterly earnings data on Monday, August 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.16. Cesca Therapeutics had a negative net margin of 322.75% and a negative return on equity of 18.05%. The business had revenue of $2.00 million for the quarter, compared to the consensus estimate of $3.00 million. research analysts forecast that Cesca Therapeutics will post 0.1 earnings per share for the current fiscal year.

About Cesca Therapeutics

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Recommended Story: Put Option

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with's FREE daily email newsletter.